Guidelines

USPSTF: No recommendation on screening for celiac disease

View on the News

Low threshold for screening considered “reasonable”

Even though the current evidence on the effectiveness of screening for celiac disease is scarce or absent, it remains reasonable for clinicians to have a low threshold for testing patients, especially in high-risk populations such as those with an affected family member or a related autoimmune disorder.

This is because most celiac disease is unrecognized, and patients can present with diverse symptoms rather than the classic triad of abdominal pain, diarrhea, and weight loss.

Dr. Joseph A. Murray

Dr. Joseph A. Murray

As less-invasive testing becomes available and gluten-free diets become more accessible to patients, reducing the burden of diagnosis and treatment, the medical research community must come forward with the data to determine who should be screened and treated and when and how they should be screened.

Rok Seon Choung, MD, and Joseph A. Murray, MD , are in the division of gastroenterology and hepatology at Mayo Clinic, Rochester, Minn. Dr. Murray reported ties to Alvine Pharmaceuticals, Alba Therapeutics, Celimmune, BioLineRx, and numerous others. Dr. Choung and Dr. Murray made these remarks in an editorial accompanying the USPSTF reports (JAMA. 2017 Mar 28;317:1221-3).


 

FROM JAMA

The current evidence is insufficient for the U.S. Preventive Services Task Force to recommend either for or against routine screening of asymptomatic people for celiac disease, according to a Recommendation Statement published online March 28 in JAMA.

However, only 4 studies out of the 3,036 that were examined addressed the question of screening adequately, and they offered few data of use. According to Roger Chou, MD, lead author of the Evidence Report, and his associates, no trials assessed the screening of asymptomatic children, adolescents, or adults for celiac disease with regard to morbidity, mortality, or quality of life. The evidence also was inadequate concerning targeted screening of at-risk individuals, and there were no studies of the effectiveness of treatment after screen-detected celiac disease was found.

There was some evidence supporting the diagnostic accuracy of the tissue transglutaminase-IgA test to detect celiac disease, but “little or no evidence ... to inform most of the key questions related to benefits and harms of screening for celiac disease in asymptomatic individuals,” said Dr. Chou, of the Pacific Northwest Evidence-Based Practice Center and Oregon Health & Science University, both in Portland, and his associates (JAMA. 2017 Mar 28. doi: 10.1001/jama.2016.10395).

Dr. Bibbins-Domingo noted that the American Academy of Family Physicians also has concluded that the evidence is insufficient to assess the balance of screening’s benefits and harms. In contrast, the American College of Gastroenterology recommends that screening be considered in asymptomatic people who have a first-degree relative with a confirmed diagnosis of celiac disease (JAMA. 2017 Mar 28. doi: 10.1001/jama.2017.1462).

In addition, the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition recommends screening at age 3 years for asymptomatic children who have conditions associated with celiac disease, including type 1 diabetes, autoimmune thyroiditis, Down syndrome, Turner syndrome, William’s syndrome, or selective IgA deficiency, said Dr. Bobbins-Domingo, who is also professor of medicine at the University of California, San Francisco.

Copies of the Recommendation Statement, the Evidence Report, the authors’ disclosures, and other materials are available at www.uspreventiveservicestaskforce.org.

Recommended Reading

AGA Clinical Practice Update: PPIs should be prescribed sparingly, carefully
MDedge Internal Medicine
VIDEO: Point-of-care assay caught acetaminophen toxicity
MDedge Internal Medicine
Open-capsule PPIs linked to faster ulcer healing after Roux-en-Y
MDedge Internal Medicine
Colorectal cancer mortality highest in W.Va., lowest in Utah
MDedge Internal Medicine
Barrett’s esophagus: Cancer risk is highest in first year after diagnosis
MDedge Internal Medicine
HCV testing stagnant among baby boomers
MDedge Internal Medicine
HCV ‘cure’ within the VA appears likely
MDedge Internal Medicine
Antiviral medication successful for treating HCV in hepatocellular carcinoma
MDedge Internal Medicine
Hepatitis Outlook: Late February 2017
MDedge Internal Medicine
PPI-responsive eosinophilic esophagitis may be misnomer
MDedge Internal Medicine